{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T15:48:31Z","timestamp":1790005711259,"version":"4.0.1"},"reference-count":24,"publisher":"Cambridge University Press (CUP)","issue":"S1","license":[{"start":{"date-parts":[[2014,11,7]],"date-time":"2014-11-07T00:00:00Z","timestamp":1415318400000},"content-version":"unspecified","delay-in-days":4603,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Spectr."],"published-print":{"date-parts":[[2002,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Serotonin (5-hydroxytryptamine, 5-HT) has long been suspected to play a role in the etiology of depression, and modern neurochemical techniques have confirmed this suspicion. Furthermore, all drugs known to be selective (a relative term) serotonin transporter (SERT) inhibitors are effective antidepressants. Of the selective serotonin reuptake inhibitors (SSRIs) approved in a number of countries for use in depression, panic disorder, and obsessive-compulsive disorder, citalopram is the most selective. Citalopram has been used worldwide to treat an estimated 35 million patients, with an excellent safety record. Citalopram is a racemic drug, and its effects on serotonin transport are thought to reside in the S-enantiomer, known as (S)-citalopram or escitalopram. Escitalopram is the most selective SSRI yet developed. Its receptor binding properties and activity in preclinical animal models of depression predict that escitalopram would be effective in the treatment of depression, with approximately twice the potency of the racemate. The pivotal clinical trials of escitalopram not only support this conclusion, but also suggest escitalopram possesses advantages over citalopram in terms of both efficacy and safety. In conclusion, escitalopram is a promising candidate for use as a first-line antidepressant.<\/jats:p>","DOI":"10.1017\/s1092852900028583","type":"journal-article","created":{"date-parts":[[2016,8,2]],"date-time":"2016-08-02T03:23:21Z","timestamp":1470108201000},"page":"34-39","source":"Crossref","is-referenced-by-count":25,"title":["Escitalopram: A Second-Generation SSRI"],"prefix":"10.1017","volume":"7","author":[{"given":"Michael J.","family":"Owens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerrold F.","family":"Rosenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2014,11,7]]},"reference":[{"key":"S1092852900028583_ref011","first-page":"43","article-title":"Affinities of fluoxetine, its enantiomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors","volume":"5","author":"Wong","year":"1991","journal-title":"Neuropsychopharmacology"},{"key":"S1092852900028583_ref005","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)91262-9"},{"key":"S1092852900028583_ref020","first-page":"1102","article-title":"Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-eitalopram","volume":"29","author":"Von Moltke","year":"2001","journal-title":"Drug Metab Dipos"},{"key":"S1092852900028583_ref022","volume-title":"Fixed dose study of escitalopram in the treatment of depression","author":"Burke","year":"2001"},{"key":"S1092852900028583_ref012","doi-asserted-by":"publisher","DOI":"10.1021\/cen-v078n044.p008"},{"key":"S1092852900028583_ref018","volume-title":"Behavioural effects of escitalopram predict potent antidepressant activity","author":"Mitchell","year":"2001"},{"key":"S1092852900028583_ref003","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.142.2.188"},{"key":"S1092852900028583_ref006","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1093\/clinchem\/40.2.288","article-title":"Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter","volume":"40","author":"Owens","year":"1994","journal-title":"Clinical Chemistry"},{"key":"S1092852900028583_ref015","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050456"},{"key":"S1092852900028583_ref021","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0410"},{"key":"S1092852900028583_ref010","doi-asserted-by":"publisher","DOI":"10.1021\/jm00402a027"},{"key":"S1092852900028583_ref024","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199902000-00013"},{"key":"S1092852900028583_ref001","volume-title":"Arzneimittel","author":"Kraepelin","year":"1892"},{"key":"S1092852900028583_ref002","doi-asserted-by":"publisher","DOI":"10.1126\/science.7079769"},{"key":"S1092852900028583_ref019","volume-title":"Escitalopram has potent anxiolytic effects in rodent anxiety models","author":"Sanchez","year":"2001"},{"key":"S1092852900028583_ref004","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1520-6394(1998)8:1+<5::AID-DA2>3.0.CO;2-I"},{"key":"S1092852900028583_ref007","first-page":"132","volume-title":"Neurobiology of Mental Illness","author":"Owens","year":"1999"},{"key":"S1092852900028583_ref008","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)90626-2"},{"key":"S1092852900028583_ref009","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/S0022-3565(25)20751-0","article-title":"Platelet 5-hydroxytryptamine (5-HT) transporter and 5-HT2A receptor binding after chronic hyper-corticosteronemia, (\u00b1)-1-(2,5-dimelhoxy-4-iodophenyl)-2-aminopropane administration or neurotoxin-induced depletion of central nervous system 5-HT in the rat","volume":"278","author":"Owens","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"S1092852900028583_ref013","doi-asserted-by":"publisher","DOI":"10.1007\/BF01244820"},{"key":"S1092852900028583_ref014","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-3223(01)01145-3"},{"key":"S1092852900028583_ref016","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0773.2001.d01-118.x"},{"key":"S1092852900028583_ref017","volume-title":"Escitalopram: potent and rapid in chronic mild stress model of depression","author":"Papp","year":"2001"},{"key":"S1092852900028583_ref023","unstructured":"Data on file, Forest Laboratories."}],"container-title":["CNS Spectrums"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S1092852900028583","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T10:55:54Z","timestamp":1749034554000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S1092852900028583\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4]]},"references-count":24,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2002,4]]}},"alternative-id":["S1092852900028583"],"URL":"https:\/\/doi.org\/10.1017\/s1092852900028583","relation":{},"ISSN":["1092-8529","2165-6509"],"issn-type":[{"value":"1092-8529","type":"print"},{"value":"2165-6509","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,4]]}}}